ROS1, RET mutations added to liquid biopsy test, 5/17

Create PDF

May 2017—Biodesix announced that its GeneStrat test, a liquid biopsy for patients with cancer, now includes ROS1 and RET. GeneStrat is a noninvasive blood test analyzing circulating tumor DNA and RNA. The test provides highly sensitive results in 72 hours for non-small cell lung cancer patients.

Physicians can use GeneStrat as part of the Biodesix Lung Reflex multi-omic, liquid biopsy testing strategy when reflexed to VeriStrat proteomic testing to identify more aggressive tumor growth and inform likely patient benefit from treatment.

Biodesix, 303-417-0500